文献速递冠心病血脂与心血管预防

血脂参数与维生素A对血浆新蝶呤心血管风险预测的影响

Lipid parameters and vitamin A modify cardiovascular risk prediction by plasma neopterin.
PubMed 文献 · Heart · 2020-05-12

本研究纳入4130例疑似稳定型心绞痛患者,其中80%接受他汀治疗,中位随访7.5年,530例(12.8%)发生急性心肌梗死。血浆新蝶呤升高与急性心肌梗死风险正相关,且在低密度脂蛋白胆固醇或载脂蛋白B100低于中位数、或维生素A高于中位数的患者中关联更强。

要点

  • 在疑似稳定型心绞痛患者中,血浆新蝶呤升高与急性心肌梗死风险增加相关。
  • 低密度脂蛋白胆固醇或载脂蛋白B100低于中位数者,新蝶呤与心梗风险关联更强。
  • 维生素A高于中位数者,新蝶呤与心梗风险关联亦更强。

核心结论

  • 在疑似稳定型心绞痛患者中,高血浆新蝶呤与急性心肌梗死风险增加相关,尤其在低密度脂蛋白胆固醇和载脂蛋白B100较低或维生素A较高的患者中。

研究设计与样本

  • 纳入4130例疑似稳定型心绞痛患者,其中80%接受他汀类降脂治疗,中位随访7.5年。

主要发现

  • 随访期间530例(12.8%)患者发生急性心肌梗死。
  • 年龄和性别调整分析中,血浆新蝶呤每增加1个标准差,急性心肌梗死风险比为1.26(95%CI 1.17至1.35)。
  • 低密度脂蛋白胆固醇低于中位数者,风险比为1.35(95%CI 1.24至1.48),交互作用P≤0.03。
  • 载脂蛋白B100低于中位数者,风险比为1.42(95%CI 1.27至1.58),交互作用P≤0.03。
  • 维生素A高于中位数者,风险比为1.32(95%CI 1.21至1.44),交互作用P=0.03。

临床怎么用

  • 在疑似稳定型心绞痛患者中,可关注血浆新蝶呤水平以辅助评估急性心肌梗死残余风险。
  • 对于血脂水平较低或维生素A较高的患者,新蝶呤与心梗风险的关联更强,可能需加强风险监测。

局限性

  • 本研究为观察性研究,无法确立因果关系。
  • 多数患者接受他汀治疗,可能影响血脂参数与新蝶呤的关联评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Oxidised cholesterol metabolites are linked to increased production of the active vitamin A (Vit-A) form and monocyte/macrophage activation, which may be reflected by neopterin, a marker of both interferon-γ-mediated immune activation and coronary artery disease risk. We examined the influence of serum lipid parameters and Vit-A on the risk association between neopterin and incident acute myocardial infarction (AMI). METHODS: We included 4130 patients with suspected stable angina pectoris (SAP), of whom 80% received lipid-lowering treatment with statins. Risk associations between plasma neopterin and AMI are given as HRs per SD increase in log-transformed neopterin. RESULTS: During a median follow-up of 7.5 years, 530 (12.8%) patients experienced an AMI. In age-adjusted and sex-adjusted analysis, plasma neopterin was positively associated with incident AMI (HR (95% CI) per SD: 1.26 (1.17 to 1.35)). However, the estimates were most pronounced in patients with serum low-density lipoprotein cholesterol (LDL-C) or apolipoprotein (apo) B100 below-median (HR (95% CI) per SD: 1.35 (1.24 to 1.48) and 1.42 (1.27 to 1.58), respectively; both pinteraction ≤0.03). We also observed a particularly strong risk association in those with above-median Vit-A (HR (95% CI) per SD: 1.32 (1.21 to 1.44); pinteraction=0.03). The estimates were slightly modified after multivariable adjustment. CONCLUSIONS: In patients with suspected SAP, the majority of whom receiving statin therapy, high plasma neopterin was associated with increased risk of AMI particularly among those with low LDL-C and apoB100 or high Vit-A levels. The particularly strong relationship of plasma neopterin with residual cardiovascular risk in patients with low lipid levels should be further investigated.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Dhar I, Siddique S, R Pedersen E, et al. Lipid parameters and vitamin A modify cardiovascular risk prediction by plasma neopterin. Heart. 2020. PMID: 32398245. doi:10.1136/heartjnl-2019-316165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。